Difference between revisions of "Tafasitamab (Monjuvi)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) |
||
| Line 14: | Line 14: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' | + | *'''Code names:''' MOR-208, MOR-00208, XmAb-5574 |
*'''Generic name:''' tafasitamab-cxix | *'''Generic name:''' tafasitamab-cxix | ||
*'''Brand name:''' Minjuvi, Monjuvi | *'''Brand name:''' Minjuvi, Monjuvi | ||
Latest revision as of 12:29, 27 July 2023
Mechanism of action
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity
Diseases for which it is used
History of changes in FDA indication
- 2020-07-31: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. (Based on L-MIND)
History of changes in EMA indication
- 2021-08-26: Initial conditional approval as Minjuvi
History of changes in Health Canada indication
- 2021-08-19: Initial notice of compliance with conditions in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT)
Also known as
- Code names: MOR-208, MOR-00208, XmAb-5574
- Generic name: tafasitamab-cxix
- Brand name: Minjuvi, Monjuvi